AR112328A1 - Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis - Google Patents
Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactisInfo
- Publication number
- AR112328A1 AR112328A1 ARP180101879A AR112328A1 AR 112328 A1 AR112328 A1 AR 112328A1 AR P180101879 A ARP180101879 A AR P180101879A AR 112328 A1 AR112328 A1 AR 112328A1
- Authority
- AR
- Argentina
- Prior art keywords
- lactis
- bifidobacterium animalis
- animalis ssp
- strain
- subject
- Prior art date
Links
- 241001134770 Bifidobacterium animalis Species 0.000 title abstract 10
- 229940118852 bifidobacterium animalis Drugs 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 241000098811 Asinibacterium lactis Species 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Reivindicación 1: Un método para tratar el cáncer en un sujeto que comprende administrar al sujeto una composición bacteriana que comprende Bifidobacterium animalis ssp. lactis. Reivindicación 2: El método de la reivindicación 1, donde Bifidobacterium animalis ssp. lactis es una cepa que comprende al menos un 99% de identidad de secuencia con la secuencia de nucleótidos de la cepa A de Bifidobacterium animalis ssp. lactis (número de depósito ATCC PTA-125097). Reivindicación 3: El método de la reivindicación 1, donde Bifidobacterium animalis ssp. lactis es una cepa que comprende al menos un 99,9% de identidad de secuencia con la secuencia de nucleótidos de la cepa A de Bifidobacterium animalis ssp. lactis (número de depósito ATCC PTA-125097). Reivindicación 4: El método de la reivindicación 1, donde Bifidobacterium animalis ssp. lactis es la cepa A de Bifidobacterium animalis ssp. lactis (número de depósito ATCC PTA-125097). Reivindicación 79: Un método para aumentar un entorno tumoral que contiene una célula inmune en un sujeto que comprende administrar una composición bacteriana que comprende Bifidobacterium animalis ssp. lactis para el sujeto. Reivindicación 91: Una composición bacteriana que comprende Bifidobacterium animalis ssp. lactis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762528669P | 2017-07-05 | 2017-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112328A1 true AR112328A1 (es) | 2019-10-16 |
Family
ID=63036353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101879 AR112328A1 (es) | 2017-07-05 | 2018-07-05 | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10792314B2 (es) |
| EP (1) | EP3648780A1 (es) |
| JP (1) | JP7254786B2 (es) |
| KR (1) | KR102563191B1 (es) |
| CN (1) | CN111356464A (es) |
| AR (1) | AR112328A1 (es) |
| AU (1) | AU2018298087A1 (es) |
| BR (1) | BR112019028301A2 (es) |
| CA (1) | CA3068757A1 (es) |
| MA (1) | MA51770A (es) |
| TW (1) | TW201906620A (es) |
| WO (1) | WO2019010255A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| WO2018215758A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| CA3066561C (en) | 2017-06-14 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus megasphera and uses thereof |
| PT3638271T (pt) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Ltd | Composições contendo estirpes bacterianas |
| CA3068757A1 (en) | 2017-07-05 | 2019-01-10 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis |
| MX2020009736A (es) | 2018-03-19 | 2021-01-08 | 4D Pharma Res Limited | Composiciones que comprenden cepas bacterianas. |
| CA3106139A1 (en) | 2018-07-16 | 2020-01-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| AU2019396657A1 (en) | 2018-12-12 | 2021-07-08 | 4D Pharma Research Limited | Compositions comprising Parabacteroides bacterial strains for treating cancer |
| US20220296654A1 (en) * | 2019-06-11 | 2022-09-22 | Evelo Biosciences, Inc | Processed microbial extracellular vesicles |
| WO2021022110A1 (en) | 2019-08-01 | 2021-02-04 | Evelo Biosciences, Inc. | Inducing immune effects using bacteria of the genus bifidobacterium |
| KR102357904B1 (ko) * | 2019-10-29 | 2022-02-04 | 경희대학교 산학협력단 | 항암용 금 나노입자 |
| CN112618577B (zh) * | 2020-12-15 | 2023-07-25 | 深圳君拓生物科技有限公司 | 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用 |
| WO2022164870A1 (en) * | 2021-01-26 | 2022-08-04 | Cb Therapeutics, Inc. | Recombinant polyprenol diphosphate synthases |
| CN113368259B (zh) * | 2021-06-22 | 2022-07-22 | 海南大学 | 一种基于修饰细菌加载纳米药物的方法及其复合物和在治疗结肠癌中的应用 |
| CN114028432A (zh) * | 2021-11-05 | 2022-02-11 | 上海市第十人民医院 | 双歧杆菌提升铂类化疗药物敏感性的药物新用途 |
| CN115363094A (zh) * | 2021-11-30 | 2022-11-22 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在预防和/或改善胃炎中的应用 |
| CN114480229B (zh) * | 2022-04-15 | 2022-08-09 | 微康益生菌(苏州)股份有限公司 | 一种动物双歧杆菌乳亚种菌株wkb148及其产品与应用 |
| CN115216423B (zh) * | 2022-06-15 | 2023-04-25 | 南昌大学 | 一种动物双歧杆菌sf及其在医药和食品中的应用 |
| CN117327632B (zh) * | 2023-12-01 | 2024-02-13 | 四川厌氧生物科技有限责任公司 | 一种动物双歧杆菌及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| PE20030284A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de bifidobacterium |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| EP1481681A1 (en) | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
| JP4683881B2 (ja) | 2003-08-27 | 2011-05-18 | 有限会社アーク技研 | 抗腫瘍活性剤 |
| GB0323039D0 (en) | 2003-10-01 | 2003-11-05 | Danisco | Method |
| EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
| US20100028449A1 (en) | 2006-06-06 | 2010-02-04 | Satya Prakash | Fermented milk product and use thereof |
| US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| RU2466185C2 (ru) | 2007-03-28 | 2012-11-10 | Элиментари Хелт Лимитед | ПРОБИОТИЧЕСКИЙ ШТАММ Bifidobacterium longum, ПРОБИОТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЯ ШТАММА Bifidobacterium longum |
| JP5538209B2 (ja) | 2007-03-28 | 2014-07-02 | アリメンタリー・ヘルス・リミテッド | プロバイオティック性のビフィドバクテリウム菌株 |
| EP1997907A1 (en) | 2007-06-01 | 2008-12-03 | Friesland Brands B.V. | Bifidobacteria |
| US20110027348A1 (en) | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
| US8658153B2 (en) | 2007-10-20 | 2014-02-25 | Universite De Liege | Bifidobacterial species |
| WO2009149149A1 (en) | 2008-06-04 | 2009-12-10 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| ES2595444T3 (es) | 2009-11-11 | 2016-12-30 | Alimentary Health Limited | Cepa de Bifidobacterium probiótica |
| WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| NZ711298A (en) * | 2013-03-14 | 2021-07-30 | Therabiome Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| EP3033091B1 (en) | 2013-08-16 | 2022-09-07 | Versitech Limited | Probiotic composition and use thereof in the prevention and treatment of hepatocellular carcinoma |
| US10203329B2 (en) | 2013-09-12 | 2019-02-12 | The Johns Hopkins University | Biofilm formation to define risk for colon cancer |
| EP2876167A1 (en) | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
| WO2015170158A1 (en) * | 2014-05-05 | 2015-11-12 | Giovanni Mogna | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation |
| CN104224851B (zh) | 2014-08-15 | 2018-08-24 | 中国农业大学 | 动物双歧杆菌乳酸亚种CGMCC No.9273的应用 |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| MX2017009532A (es) | 2015-01-23 | 2018-04-10 | Univ Temple | Uso de acidos grasos de cadena corta en prevencion de cancer. |
| EP3285777B1 (en) | 2015-04-23 | 2021-06-09 | Kaleido Biosciences, Inc. | Glycan therapeutics and methods of treatment |
| EP3285778A2 (en) | 2015-04-23 | 2018-02-28 | Kaleido Biosciences, Inc. | Microbiome regulators and related uses thereof |
| TW201717975A (zh) | 2015-06-01 | 2017-06-01 | 美國芝加哥州立大學 | 藉由控制共生微生物叢來治療癌症 |
| EP3650033B1 (en) | 2015-06-15 | 2022-02-16 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CN106110322A (zh) * | 2016-07-29 | 2016-11-16 | 安徽瀚海博兴生物技术有限公司 | 一种药物组合物及其在制备治疗癌症药物中的应用 |
| CA3068757A1 (en) | 2017-07-05 | 2019-01-10 | Evelo Biosciences, Inc. | Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis |
-
2018
- 2018-07-05 CA CA3068757A patent/CA3068757A1/en active Pending
- 2018-07-05 TW TW107123313A patent/TW201906620A/zh unknown
- 2018-07-05 WO PCT/US2018/040841 patent/WO2019010255A1/en unknown
- 2018-07-05 US US16/027,684 patent/US10792314B2/en active Active
- 2018-07-05 AU AU2018298087A patent/AU2018298087A1/en not_active Abandoned
- 2018-07-05 JP JP2020521493A patent/JP7254786B2/ja active Active
- 2018-07-05 CN CN201880057669.0A patent/CN111356464A/zh active Pending
- 2018-07-05 EP EP18746378.1A patent/EP3648780A1/en active Pending
- 2018-07-05 KR KR1020207003258A patent/KR102563191B1/ko active IP Right Grant
- 2018-07-05 MA MA051770A patent/MA51770A/fr unknown
- 2018-07-05 BR BR112019028301-3A patent/BR112019028301A2/pt unknown
- 2018-07-05 AR ARP180101879 patent/AR112328A1/es unknown
-
2019
- 2019-04-05 US US16/376,253 patent/US10576111B2/en not_active Expired - Fee Related
-
2020
- 2020-08-26 US US17/003,640 patent/US20210093680A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201906620A (zh) | 2019-02-16 |
| US20190192585A1 (en) | 2019-06-27 |
| JP2020526581A (ja) | 2020-08-31 |
| WO2019010255A1 (en) | 2019-01-10 |
| US10576111B2 (en) | 2020-03-03 |
| CN111356464A (zh) | 2020-06-30 |
| US10792314B2 (en) | 2020-10-06 |
| US20210093680A1 (en) | 2021-04-01 |
| KR102563191B1 (ko) | 2023-08-02 |
| BR112019028301A2 (pt) | 2020-07-14 |
| EP3648780A1 (en) | 2020-05-13 |
| MA51770A (fr) | 2020-05-13 |
| KR20200024911A (ko) | 2020-03-09 |
| US20190224253A1 (en) | 2019-07-25 |
| JP7254786B2 (ja) | 2023-04-10 |
| CA3068757A1 (en) | 2019-01-10 |
| AU2018298087A1 (en) | 2020-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112328A1 (es) | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis | |
| MX2019008196A (es) | Microorganismos programados para producir moduladores inmunes y productos terapéuticos anti-cáncer en células tumorales. | |
| AR111207A1 (es) | Anticuerpos anti-lag3 | |
| AR110684A1 (es) | Composiciones que comprenden cepas bacterianas y método de tratamiento | |
| MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
| PH12020551437A1 (en) | Methods for treating hpv-associated diseases | |
| WO2019033043A3 (en) | ANTI-CD8 ANTIBODIES AND USES THEREOF | |
| MX2021002415A (es) | Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas. | |
| WO2017123675A8 (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| BR112016024352A2 (pt) | ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? | |
| WO2018083220A3 (en) | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines | |
| MX2022007775A (es) | Composición para usarse en terapia de microbiota. | |
| MX2016012891A (es) | Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido. | |
| Helmy et al. | Immuno-modulatory effect of probiotic E. coli Nissle 1917 in polarized human colonic cells against Campylobacter jejuni infection | |
| NZ713423A (en) | Bacteriophage therapy | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| MX2021012004A (es) | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. | |
| RU2015105738A (ru) | Непатогенный штамм f18 е. coli и его применение | |
| AR107475A1 (es) | Cepas fúngicas solubilizantes de fosfato | |
| EP4253419A3 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| BR112018074299A2 (pt) | composições farmacêuticas compreendendo eteplirsen | |
| MX2020013621A (es) | Composiciones y metodos de tratamiento de vih. | |
| MX2019003258A (es) | Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana. | |
| BR112017024065A2 (pt) | método para tratar insuficiência cardíaca avançada em um indivíduo humano | |
| MX2021002500A (es) | Anticuerpos y secuencias de nucleotidos novedosos, y sus usos. |